Archive · 17 Nov 2025
Russia's Enteromix: Promising Cancer Vaccine Raises Hope and Caution
Scientists in Russia have created a new kind of medicine called a vaccine to fight cancer.
It uses a technology similar to the COVID-19 vaccines, called mRNA.
This vaccine teaches your body's defense system to find and destroy cancer cells.
Early tests say it works perfectly and is safe for people, but these tests were on a small number of people and mainly for one type of cancer.
Doctors are excited but also cautious because it's still new and not available everywhere, especially in India.
They say it's important to wait for more complete testing and approval before calling it a cure, as cancer is a very complex disease.
Russia announces Enteromix, an mRNA cancer vaccine with claimed 100% efficacy and safety in initial human trials.
The vaccine uses mRNA technology to train the immune system to identify and eliminate cancer cells, presenting a potentially safer alternative to chemotherapy.
Enteromix has primarily been tested on colorectal cancer patients in small Phase-I trials involving 48 participants.
Medical professionals urge caution, noting the need for full clinical performance data and rigorous trials before widespread use or approval.
The Enteromix vaccine is not currently available in India and requires stringent regulatory approval processes.
- Who
- Russian researchers and oncologists, including Dr. Ruchir Bhandari and Dr. Rajesh Bollam
- What
- Development and claims of a new mRNA-based cancer vaccine called Enteromix, which reportedly shows 100% efficacy and safety in initial human trials.
- When
- Recently, with initial human trials conducted.
- Where
- Russia, with potential interest from India.
- Why
- To develop a novel and potentially more effective and safer method than traditional treatments like chemotherapy to combat cancer by training the immune system.
Enthusiastic Promoters/Potential Patients
Medical Professionals and Regulatory Bodies
Efficacy and Safety Claims
Enthusiastic Promoters/Potential Patients
Early reports and claims suggest the Enteromix vaccine has shown 100% efficacy and safety in initial human trials, utilizing advanced mRNA technology.
Medical Professionals and Regulatory Bodies
Doctors emphasize that the vaccine has only been tested on a small number of patients (48), primarily for colorectal cancer, and full clinical performance and long-term safety data remain undisclosed. It has not undergone rigorous trials or regulatory approval for use in India.
Availability and Accessibility
Enthusiastic Promoters/Potential Patients
There is significant interest and willingness from cancer patients and their families to obtain the vaccine, even if it means incurring costs and procuring it from abroad.
Medical Professionals and Regulatory Bodies
The vaccine is not currently available in India and would require successful human trials, regulatory approvals, and verification of safety and efficacy data before it could be considered for use. Patients are advised to consult oncologists and be wary of exaggerated claims.
Universal Cancer Cure
Enthusiastic Promoters/Potential Patients
The development of mRNA cancer vaccines offers a revolutionary future where the immune system could be harnessed to fight tumors.
Medical Professionals and Regulatory Bodies
Cancer's complexity means a universal cure is unlikely; while advances are being made, cancer remains a complex disease, and a one-size-fits-all solution is not feasible. Current treatments, combined with early detection, are making cancer a more manageable chronic disease.
- Vaccine Name
- Enteromix
- Developer
- Russia
- Technology
- mRNA
- Target Cancers
- Colorectal cancer (initial focus), glioblastoma, certain melanomas (planned)
- Claimed Efficacy
- 100%
- Trial Size
- 48 patients (Phase-I)
- Availability in India
- Not yet available